investigation on anticataract activity of triphala ghrita
Clicks: 5
ID: 193933
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #218 of 235 articles by views in Journal of pharmaceutical and biomedical analysis
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 235 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Lab prepared Triphala ghrita was studied for its possible anticataract activity on galactose induced cataract in Swiss albino rats. Administration of Triphala ghrita at a dose of 216 mg/200 g, 1080 mg/200 g and 2160 mg/200 g of rat orally offered significant dose dependent protection against galactose induced cataract and delayed the onset and progression of cataract. It was seen that the dose of 1080 mg of Triphala ghrita did not show stage II cataract in 14 days and stage III in 21 days. It did not show even stage III and stage IV cataract after 30 days whereas group B and group C showed stage III and stage IV cataracts. Dose of 2160 mg did not showed stage IV cataract after 30 days but showed stage III cataract. Dose of 1080 mg of Triphala ghrita offered significant protection against delaying the onset and progression of cataract in comparison to other doses. This effect may be attributed to the antioxidant activity of gallic acid, ellagic acid and ascorbic acid which shows their presence in Triphala ghrita. This preliminary study was encouraging but further studies are required to extrapolate the clinical usefulness of this formulation.
| Reference Key |
mahajan2011e-journalinvestigation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;K. N. Mahajan;A. K. Singhai;G. P. Vadnere |
| Journal | Journal of pharmaceutical and biomedical analysis |
| Year | 2011 |
| DOI |
10.1155/2011/571627
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.